Citius Oncology (CTOR) Shares Outstanding (2021 - 2026)

Citius Oncology (CTOR) has reported Shares Outstanding (Entity) for 6 consecutive years, with $105.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 47.81% year-over-year to $105.8 million in Q2 2026; TTM through Jun 2026 was $105.8 million, a 47.81% increase from a year earlier, with the FY2025 full-year figure at $83.5 million, up 16.72% from the prior year.
• Shares Outstanding (Entity) was $105.8 million for Q2 2026 at Citius Oncology, up from $93.0 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $105.8 million in Q2 2026 and troughed at $1.7 million in Q3 2022.
• A 5-year average of $47.8 million and a median of $69.5 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) surged 2004.62% in 2023 and slumped 47.43% in 2024, its largest moves.
• Over 5 years, Shares Outstanding (Entity) stood at $3.2 million in 2022, then surged by 2004.62% to $67.5 million in 2023, then climbed by 6.0% to $71.6 million in 2024, then gained by 18.51% to $84.8 million in 2025, then increased by 24.72% to $105.8 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $105.8 million (Q2 2026), $93.0 million (Q1 2026), and $84.8 million (Q4 2025), per Business Quant data.